



Cremophor EL: the drawbacks and advantages of vehicle selection for drug formulation

H. Gelderblom*, J. Verweij, K. Nooter, A. Sparreboom

Department of Medical Oncology, Rotterdam Cancer Institute (Daniel den Hoed Kliniek) and University Hospital Rotterdam, 3075 EA Rotterdam, The Netherlands

Received 26 February 2001; received in revised form 26 March 2001; accepted 3 May 2001

Abstract

Cremophor EL (CrEL) is a formulation vehicle used for various poorly-water soluble drugs, including the anticancer agent paclitaxel (Taxol). In contrast to earlier reports, CrEL is not an inert vehicle, but exerts a range of biological effects, some of which have important clinical implications. Its use has been associated with severe anaphylactoid hypersensitivity reactions, hyperlipidaemia, abnormal lipoprotein patterns, aggregation of erythrocytes and peripheral neuropathy. The pharmacokinetic behaviour of CrEL is dose-independent, although its clearance is highly influenced by duration of the infusion. This is particularly important since CrEL can affect the disposition of various drugs by changing the unbound drug concentration through micellar encapsulation. In addition, it has been shown that CrEL, as an integral component of paclitaxel chemotherapy, modifies the toxicity profile of certain anticancer agents given concomitantly, by mechanisms other than kinetic interference. A clear understanding of the biological and pharmacological role of CrEL is essential to help oncologists avoid side-effects associated with the use of paclitaxel or other agents using this vehicle. With the present development of various new anticancer agents, it is recommended that alternative formulation approaches should be pursued to allow a better control of the toxicity of the treatment and the pharmacological interactions related to the use of CrEL. © 2001 Elsevier Science Ltd. All rights reserved.

Keywords: Cremophor EL; Formulation vehicles; Paclitaxel; Pharmacokinetics; Pharmacodynamics

1. Introduction

The choice of a suitable pharmaceutical formulation is an essential step in anticancer drug development. This development starts with the acquisition of a chemical entity from either natural sources or entirely synthetic routes. Subsequently, the compound is screened for cytotoxic activity *in vitro* and *in vivo*. Once the screening process has been completed the compound should be properly pharmaceutically-formulated and produced before entering animal toxicology and pharmacokinetic studies and subsequently human phase I, II and III studies [1,2]. In our opinion, pharmaceutical formulation is a seriously underrated aspect of anticancer drug development.

With only a few exceptions, most new anticancer compounds are initially developed for intravenous (i.v.)

use, despite some drawbacks such as the morbidity associated with gaining i.v. access, risk of i.v. catheter-related infection, thrombosis and extravasation, and patients' preference for oral therapy when equally effective [3]. Important reasons for choosing i.v. use for initial drug development are the fact that usually less gastrointestinal toxicity occurs, there is immediate 100% bioavailability and instantaneous pharmacodynamic effects and there is a possibility to modify the dosing rate or even halt the infusion if necessary. Solubility of the compound is a specific demand for i.v. administration, even for the newer chemotherapeutic agents which are known to be poorly water-soluble. Classical solubility approaches, which will be discussed subsequently, include the use of colloidal systems, pro-drug development or solubilisation techniques.

Colloidal systems such as liposomes, microcapsules, microspheres, nanoparticles or macromolecule complexes may protect the anticancer drug from premature degradation or (chemical) inactivation within the systemic circulation. Prodrugs are inactive derivatives that

* Corresponding author. Tel.: +31-10-439-1754; fax: +31-10-439-1003.

E-mail address: gelderblom@onch.azr.nl (H. Gelderblom).

release the active drug following spontaneous degradation or enzymatic reactions. Solubilisation is the process of uptake of drugs through complex formation into for, e.g. oligomers of dextrose and fatty acids, through co-solvent systems (such as ethanol, polyethyleneglycol and glycerol), or through surfactant systems. The surfactant systems consist of either amphoteric compounds (e.g. lecithin or gelatin), ionic surfactants (e.g. sodium palmitate) or non-ionic surfactants (e.g. Tween 80 and Cremophor EL (CrEL)) [4,5]. This review focuses on biological and pharmacological properties of CrEL, which is the formulation vehicle of various hydrophobic drugs, including the anticancer agent paclitaxel.

2. Paclitaxel formulation

After the identification of paclitaxel as the active ingredient in crude ethanolic extracts of the bark of the Western Yew tree, *Taxus brevifolia*, against several murine tumours [6], the development of the drug was suspended for more than a decade due to problems associated with the solubilisation of the drug. Paclitaxel is insoluble in water (less than 0.03 mg/ml), slightly soluble in octanol, propylene glycol and butanol, soluble in CrEL, ethanol, methanol, chloroform, acetone and ether, and freely soluble in dimethyl acetamide. The formulation approach using 50% CrEL and 50% dehydrated ethanol United States Pharmacopeia (USP) was chosen for further development [7]. The pharmaceutical formulation of paclitaxel (paclitaxel; Bristol-Myers Squibb) contains 30 mg paclitaxel dissolved in 5 ml of this (1:1, v/v) mixture.




Fig. 1. Chemical structures of paclitaxel (a) of CrEL (polyoxyethyleneglycerol triricinoleate 35) (b).

The heterogeneous non-ionic surfactant CrEL is a white to off-white viscous liquid with an approximate molecular weight of ~3 kDa and a specific gravity (25°C/25°C) of 1.05–1.06, and it is produced by the reaction of castor oil with ethylene oxide at a molar ratio of 1:35 [4]. Castor oil is a colourless or pale yellow fixed oil obtained from the seeds of *Ricinus communis*, with an extremely high viscosity, and consists mainly of the glycerides of ricinoleic, isoricinoleic, stearic and dihydroxystearic acids. CrEL is usually of highly variable composition, with the major component identified as oxylated triglycerides of ricinoleic acid (i.e. polyoxyethylene glycerol triricinoleate 35) (Fig. 1). Polyvinyl chloride (PVC)-free equipment for CrEL administration is obligatory, since CrEL is known to leach plasticizers from PVC infusion bags and polyethylene-lined tubing sets which can cause severe hepatic toxicity [5].

CrEL is being used as a vehicle for the solubilisation of a wide variety of hydrophobic drugs, including anaesthetics, photosensitisers, sedatives, immunosuppressive agents and (experimental) anticancer drugs (Table 1). The amount of CrEL administered with these drugs averages 5 ml (range, 1.5–10.3 ml), although paclitaxel is an exception as the amount of CrEL is much higher per administration, approximately 26 ml. Therefore, it is important to understand the biological and pharmacological behaviour of CrEL, especially in the formulation of paclitaxel.

3. Biological effects of Cremophor EL (CrEL)

3.1. Anaphylactic hypersensitivity reactions

The most well known biological effect of paclitaxel formulated with CrEL is a clinical acute hypersensitivity reaction, characterised by dyspnoea, flushing, rash, chest pain, tachycardia, hypotension, angio-oedema, and generalised urticaria. Despite premedication, consisting of high-dose corticosteroids, H₁ and H₂ antagonists, minor reactions (flushing and rash) still occur in

Table 1
Examples of surfactant systems using CrEL

Agent	Therapeutic class	Amount administered ^a (ml)
Aplidine	Antineoplastics	~1.5
C8KC	Photosensitisers	5.5
Clanfenuur	Antineoplastics	10.3
Cyclosporin A	Immunosuppressives	3.5
Diazepam	Sedatives	1.5
Didemnin B	Antineoplastics	2.0
Paclitaxel	Antineoplastics	25.8
Propofol	Anaesthetics	~7.0
Teniposide	Antineoplastics	1.5

CrEL, Cremophor EL.

^a For an average patient for a single administration of dose.

41–44% of all patients and major, potentially life-threatening, reactions in 1.5–3% [8–10]. Mostly, the hypersensitivity reaction occurs within the first two courses of paclitaxel and can be prevented by reducing the infusion rate. Various (pre)clinical observations, discussed below, point to CrEL as the main contributor to the hypersensitivity reactions:

- (a) Using an elegant series of *in vitro* studies, complement activation by CrEL was found to cause the hypersensitivity reaction associated with paclitaxel chemotherapy [11], as well as reactions seen to other drugs where CrEL was used as a vehicle [12,13]. Recently, it was shown that the CrEL-induced complement activation in human serum was clearly concentration-dependent with a minimum activating CrEL level in the order of 2 µl/ml, a concentration readily achieved clinically in the plasma following standard doses of paclitaxel [14].
- (b) Histamine release in dogs by CrEL was mainly caused by one of its (minor) constituents, oleic acid [15], whereas the cardiac toxicity attributed to paclitaxel, mainly asymptomatic rhythm disturbances, might also be caused by CrEL through a mechanism of histamine release [16].
- (c) Improper mixing of high-dose cyclosporin A infusions caused (non-solubilised) CrEL to sink to the bottom of vials, producing anaphylactoid responses because of highly concentrated CrEL at the initial i.v. bolus [17]. All patients allergic to i.v. cyclosporin A, tolerated the CrEL-free oral formulation [18].
- (d) Finally, the fact that CrEL concentrations are lower with prolonged paclitaxel infusion schemes (see below) may be an explanation for the lower incidence of hypersensitivity reactions with these schemes. Collectively, these findings indicate that CrEL plays a crucial role in the occurrence of hypersensitivity reactions of paclitaxel and other drugs using CrEL as a formulation vehicle.

3.2. Lipoprotein patterns and hyperlipidaemia

Lipoprotein alterations accompanying the administration of miconazole formulated with CrEL were reported as early as 1977 by Bagnarello and colleagues [19]. Later, CrEL was found to alter the buoyant density of high-density lipoproteins (HDL) [20] and shift the electrophoretic and density gradient HDL to low density lipoproteins (LDLs) [21–23]. These authors showed that paclitaxel had a strong affinity for the serum lipoprotein dissociation products, potentially affecting the biodistribution and clearance of the drug. High concentrations of CrEL may also cause hyperlipidaemia, possibly resulting in Rouleaux formation of erythrocytes

and a change in shape of leucocytes in blood smears [24]. This suggests that manual blood-cell count analysis is warranted after the administration of preparations containing CrEL. Whether the observed hyperlipidaemia after CrEL administration increases the risk of vascular accidents is, as yet, unknown.

3.3. Neurotoxicity

Axonal degeneration and demyelination, one of the principal side-effects of paclitaxel resulting in peripheral neuropathy, is also supposedly a biological effect caused by CrEL. The plasma levels of CrEL achieved after therapeutic doses of paclitaxel and i.v. cyclosporin A (also formulated in CrEL), have been shown to produce axonal swelling, vesicular degeneration and demyelination in rat dorsal ganglion neurones [25]. Interestingly, in rats treated with CrEL-free [³H]-paclitaxel, paclitaxel was not detectable in the peripheral nervous system, indicating that the anticancer drug itself might not be responsible for the observed toxicity [26]. The hypothesis of CrEL-induced neurotoxicity is further supported by the fact that i.v. cyclosporin A causes neurotoxicity in approximately 25% of patients [27], while this side-effect is rarely seen with oral administration. This is also consistent with a previous finding that CrEL is not absorbed when given orally as a result of intestinal degradation [28]. It is also noteworthy that neurological symptoms are 10 times less common after treatment with docetaxel, a semi-synthetic taxane chemically similar to paclitaxel, than with paclitaxel [29]. This could be because unlike paclitaxel, docetaxel is formulated in Tween 80 (i.e. polyoxyethylenesorbitan monooleate), again rendering CrEL as the likely cause of the clinical observations of neuropathy. The neurotoxic properties of CrEL are most likely induced by residual unsaturated fatty acids, possibly due to the appearance of peroxidation products [30]. Therefore, it is suggested that the ethoxylated derivatives of castor oil account for most of the neuronal damage observed [31].

3.4. Reversal of P-glycoprotein activity

In the early 1990s, several groups independently observed that CrEL was able *in vitro* to modulate the activity of P-glycoprotein, a drug-transporting membrane protein that is elevated in tumour cells having a multidrug resistance phenotype [32–35]. More recently, similar phenomena have also been described for various other non-ionic surfactants, including Tween 80 [36], Solutol HS 15 [37] and Triton X-100 [38]. Surprisingly, however, multidrug resistance has never been successfully modified *in vivo* by any non-ionic surfactant, including CrEL [39–41]. A possible explanation for this lack of *in vivo* efficacy is the extremely low volume of distribution of CrEL, approximately equal to the

volume of the blood compartment, suggesting that concentrations necessary to affect reversal of multidrug resistance *in vitro* are probably not attained *in vivo* in (solid) tumours [42]. Recent pharmacokinetic experiments conducted in *mdr1a* P-glycoprotein knockout mice support this lack of efficacy, despite high peak plasma levels of CrEL [28]. In contrast to treatment in solid tumours, the pharmacokinetic selectivity of CrEL for the central blood/bone marrow compartment can be an advantage in the treatment of haematological malignancies, in which the expression of P-glycoprotein is known to be a principal factor contributing to resistance to chemotherapy [43].

3.5. *In vitro* cytotoxicity

Cytotoxic properties of CrEL in doxorubicin-resistant human breast-cancer cell lines were first reported by Fjällskog and colleagues [44], and confirmed in various human tumour samples [45,46]. It was postulated that formation of free radicals by peroxidation of polyunsaturated fatty acids and/or a direct perturbing effect in the cell membrane causing fluidity and leakage are possible mechanisms contributing to this type of cytotoxicity [47–49]. Using clonogenic assays, however, it has been demonstrated that CrEL can antagonise the cytotoxicity of paclitaxel by blocking the cell-cycle that results in the inhibition of cytokinesis [50]. Thus, although CrEL in itself might have some potential to affect cell survival, the concentrations required to modulate cell growth will also change paclitaxel-mediated (and overall) cytotoxicity. In addition, the pharmacokinetic selectivity of CrEL most likely precludes any vehicle-mediated change in (solid) tumour cell kill *in vivo*.

4. Pharmacokinetics of CrEL

4.1. Analytical methods

In view of the contribution of CrEL to clinically observed effects, and to enable further assessment of the impact of its use on paclitaxel pharmacology, the kinetic behaviour of CrEL has been studied extensively in recent years. For this purpose, a variety of analytical methods have been developed. The first assay developed for the measurement of CrEL concentrations in plasma was based on the ability of CrEL to modulate daunorubicin efflux in multidrug resistant T-cell leukaemia VLB₁₀₀ cells [51]. Later, a more sensitive and reliable method was developed, which required only microvolumes (20 μ l) of plasma [52]. This method is based on the measurement of ricinoleic acid after saponification of CrEL followed by precolumn derivatisation and reversed-phase high-performance liquid chromatography.

Because of the high costs, and time consuming nature of both assays a new method, based on a selective binding of CrEL to the Coomassie brilliant blue G-250 dye in protein-free extracts, was developed [53,54]. Most recently, an electrochemical detection method was developed [55]. Large-scale pharmacokinetic studies have only recently been possible with the development of these newer methods.

4.2. CrEL Disposition

Clinical pharmacokinetic studies with CrEL following 3-h paclitaxel infusions indicate a dose-independent behaviour with a terminal disposition half-life of approximately 80 h, with a large range depending on the method used for measurement [56,57]. Interestingly, with prolongation of the duration of infusion from 1 to 3 and to 24 h, the CrEL clearance increased from 1 to 3 and to 24 h, the CrEL clearance increased from approximately 160 to 300 to 400 ml/h/m², respectively [14] (Fig. 2). It thus appears that CrEL shows a linear and dose-independent, but schedule-dependent pharmacokinetic behaviour, possibly related to the saturation of serum esterase-mediated metabolic degradation. This schedule dependency leads to an increase in systemic exposure, and thus an increase in the possible CrEL-related biological (side-)effects with a shortening of the infusion duration. An example of this phenomenon is the higher risk of allergic reactions in the 1-h versus 3-h or 24-h infusions of paclitaxel.

As mentioned earlier, the volume of distribution of CrEL is extremely low, implying that the tissue (and tumour) delivery of CrEL is probably insignificant. This is in line with observations that CrEL levels in normal and tumour tissue were not detectable in mice [58].

Not much is known about the elimination routes of CrEL. CrEL may be largely degraded in the blood compartment by serum carboxylesterase-induced degradation, similar to that described for Tween 80 [59], causing a gradual release of the ricinoleic acid residues




Fig. 2. Schedule-dependency for CrEL clearance (CL) as a function of the duration of infusion in cancer patients treated with paclitaxel at dose of 135 (CrEL: 11.3 ml/m²), 175 (CrEL: 14.6 ml/m²) and 225 (CrEL: 18.8 ml/m²) mg/m² [14].

attached to the triglyceride structure. It has been shown that hepatobiliary elimination of CrEL is a minor elimination pathway [60]. In addition, the urinary excretion of CrEL accounted for less than 0.1% of the administered dose, in spite of its relatively hydrophilic nature [61].

4.3. Effects of CrEL on drug disposition

Various studies have shown that CrEL alters the pharmacokinetics of many drugs including cyclosporin A, etoposide, doxorubicin, a number of photosensitisers (e.g. C8KC) and paclitaxel. Initially, the effect of CrEL on the disposition of paclitaxel was studied in mice that received the drug by i.v. injection at doses of 2, 10 and 20 mg/kg in the presence of various amounts of CrEL [58] (Fig. 3). The paclitaxel clearance of 2.4 l/h/kg at the lowest dose level was reduced to 0.33 and 0.15 l/h/kg at the 10 and 20 mg/kg dose levels. It was also shown that the area under the concentration time curve (AUC) of paclitaxel is higher when it is formulated in CrEL compared with formulation in Tween 80, suggesting that CrEL is responsible for the non-linearity of paclitaxel disposition. Despite the fact that much higher plasma levels of paclitaxel are reached when given in the CrEL-containing formulation, the tissue levels of paclitaxel were essentially similar with all tested preparations, indicating that the profound influence of CrEL is only taking place in the central blood compartment. In subsequent years, numerous causes of this apparent non-linear pharmacokinetic behaviour were proposed. It has been suggested that CrEL might interfere with P-glycoprotein-mediated biliary secretion, thereby reducing paclitaxel elimination [62]. In the isolated perfused rat liver, CrEL inhibited the hepatic elimination of paclitaxel, primarily preventing the drug from reaching the sites of metabolism and excretion [63]. However, recent studies indicate that drug-transporting P-glycoproteins are not essential *per se* for normal hepatobiliary secretion of paclitaxel [28,64] and that, as discussed, the dis-




Fig. 3. Effect of the formulation vehicle (CrEL, Tween 80 or dimethylacetamide (DMA)) on paclitaxel concentration in female FVB mice receiving paclitaxel at a dose of 10 mg/kg [58].

position of CrEL itself limits the potential to modulate P-glycoprotein activity *in vivo* [42].

More recently, it has been proposed that the effect of CrEL on paclitaxel pharmacokinetics is associated with encapsulation of the drug within CrEL micelles, causing (concentration-dependent) changes in cellular partitioning and blood:plasma concentration ratios of paclitaxel [64] (Fig. 4). It was shown that the affinity of paclitaxel was (in decreasing order) CrEL > plasma > human serum albumin, with CrEL present above the critical micellar concentration (i.e. ~0.01%). Since this effect was also observed in the absence of plasma proteins, it could not have been caused by altered protein binding or by an increased affinity of paclitaxel for protein dissociation products that are produced by the action of CrEL on native lipoproteins [22]. These findings are consistent with the hypothesis that paclitaxel can be entrapped within micelles (composed primarily of polyethyleneglycerol triricinoleate) and that these micelles act as the principal carrier of paclitaxel in the systemic circulation. The percentage of total paclitaxel trapped in micelles increases disproportionately with higher doses of CrEL administered.

The hypothesis that the non-linear pharmacokinetics of paclitaxel is related to time-varying CrEL concentrations was recently confirmed in a group of cancer patients all receiving increasing doses of 135, 175 and 225 mg/m² [65]. Again, the plasma clearance of paclitaxel turned out to be dose-dependent with the slowest clearance at the highest dose level (Fig. 5). In line with the *in vitro* data, the non-linear disposition of paclitaxel in the plasma appeared to be an artifact caused by dose-related levels of CrEL in blood [65]. Therefore, the non-micellar bound or unbound fraction of paclitaxel in plasma might be a better pharmacokinetic parameter to predict toxicity and to guide dosing of paclitaxel, since it is generally acknowledged that the unbound fraction of a drug is capable of diffusing across biological barriers and interacting with essential structures in (tumour) tissues [66].




Fig. 4. Effect of the CrEL concentration on the fraction of unbound paclitaxel (fu) in human plasma [56].

Explore Litigation Insights

Docket Alarm provides insights to develop a more informed litigation strategy and the peace of mind of knowing you're on top of things.

Real-Time Litigation Alerts



Keep your litigation team up-to-date with **real-time alerts** and advanced team management tools built for the enterprise, all while greatly reducing PACER spend.

Our comprehensive service means we can handle Federal, State, and Administrative courts across the country.

Advanced Docket Research



With over 230 million records, Docket Alarm's cloud-native docket research platform finds what other services can't. Coverage includes Federal, State, plus PTAB, TTAB, ITC and NLRB decisions, all in one place.

Identify arguments that have been successful in the past with full text, pinpoint searching. Link to case law cited within any court document via Fastcase.

Analytics At Your Fingertips



Learn what happened the last time a particular judge, opposing counsel or company faced cases similar to yours.

Advanced out-of-the-box PTAB and TTAB analytics are always at your fingertips.

API

Docket Alarm offers a powerful API (application programming interface) to developers that want to integrate case filings into their apps.

LAW FIRMS

Build custom dashboards for your attorneys and clients with live data direct from the court.

Automate many repetitive legal tasks like conflict checks, document management, and marketing.

FINANCIAL INSTITUTIONS

Litigation and bankruptcy checks for companies and debtors.

E-DISCOVERY AND LEGAL VENDORS

Sync your system to PACER to automate legal marketing.